VVOSVVOSHealthcare · Medical Devices

VVOS Stock Forecast: Vivos Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.05
−8.26% on the day

The median 12-month analyst price target for Vivos Therapeutics, Inc. is $1.93. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$1.9M
Ticker Nerd rank
43/ 100
Median analyst target
$1.93
Analysts covering
2
Revenue$5.2M+34.9% y/y
Operating income−$4.8M
Net income−$5.5M
Free cash flow−$3.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−46.7%
1M
−63.0%
YTD
−97.4%
1Y
−97.5%
From 52W high
−97.9%
From 52W low
0.0%
$0.05
$2.53
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Vivos Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
43/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
77
Revisions
71
Issuance
53
Growth
48
Quality
32
Volatility
17
Value
14
Momentum
2

Accruals (77): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VVOS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VVOS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00Jan 26Apr 26Jul 26Oct 26VVOSHigh $3.10Median $1.93Low $0.75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
1
Buy
1
Hold
0
Sell
$0.75
Low
$1.93
Median
$3.10
High
Recent analyst actionsNewest first

Of the 16 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
4 June 2026Ascendiant CapitalMaintainsBuy$3.00 → $3.10
22 Apr 2026Ascendiant CapitalMaintainsBuy—
17 Apr 2026HC Wainwright & Co.MaintainsBuy—
17 Apr 2026HC Wainwright& Co.MaintainsBuy—
3 Dec 2025Ascendiant CapitalMaintainsBuy—
17 Nov 2025HC Wainwright & Co.InitiatesBuy—
9 Sept 2025Ascendiant CapitalMaintainsBuy—
15 Apr 2025Ascendiant CapitalMaintainsBuy—
20 Nov 2024Ascendiant CapitalReiteratesBuy—
19 Nov 2024Alliance Global PartnersMaintainsBuy—
20 Aug 2024Ascendiant CapitalMaintainsBuy—
17 Jan 2023Ascendiant CapitalInitiatesBuy$2.50
13 Aug 2021Roth CapitalMaintainsBuy$11 → $10
18 May 2021Roth CapitalMaintainsBuy$12 → $11
11 Jan 2021Craig-HallumInitiatesBuy—
5 Jan 2021Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for VVOS.

Market Radar

This page is one stock. Monday covers all of them.

VVOS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VVOS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Vivos Therapeutics, Inc. returned −97.5% against +6.9% for the S&P 500, dividends included.

VVOS vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26VVOSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VVOS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.1×

Cheaper than 95% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
34.9%

Higher than 80% of US stocks

Earnings growth (YoY)
—
Gross margin
57.3%

Higher than 70% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−56.2%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vivos Therapeutics, Inc. has a market value of $1.9M and an enterprise value of $13.3M.

  • Revenue in the twelve months to 30 June 2026: $20.9M. The latest quarter grew 34.9% year on year.

  • Net income over the same four quarters: −$25.6M, a −122.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$19.0M.

  • Shares outstanding: 13.5M.

  • Vivos Therapeutics, Inc. employs 268 people — $78K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

VVOS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
VVOSVivos Therapeutics, Inc.$1.9M43
PFSAProfusa, Inc.$1.8M19
NUWENuwellis, Inc.$1.8M18
AMIXAutonomix Medical, Inc.$1.7M31
BJDXBluejay Diagnostics, Inc.$1.9M17
ADGMAdagio Medical Holdings, Inc.$1.7M24
NXLNexalin Technology, Inc.$1.7M24

Take a look at VVOS’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Vivos Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VVOS

What is the VVOS stock price forecast for 2026-2027?

The median 12-month analyst price target for Vivos Therapeutics, Inc. is $1.93, with estimates ranging from $0.75 to $3.1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VVOS stock a buy right now?

Of the 2 analysts covering Vivos Therapeutics, Inc., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vivos Therapeutics, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VVOS?

As at 21 Nov 2026, Vivos Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (77 of 100).

Will VVOS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $1.93, and Ticker Nerd's factor model ranks Vivos Therapeutics, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VVOS stock forecast for 2030?

No analyst covering Vivos Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VVOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.75 to $3.1 over the next 12 months.

How has VVOS stock performed over the past year?

Vivos Therapeutics, Inc. returned -97.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vivos Therapeutics, Inc. do?

Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on addressing dentofacial abnormalities, obstructive sleep apnea, and snoring through non-invasive treatment solutions. The company develops and commercializes the Vivos Method, an oral appliance-based approach used by trained dental and medical professionals to support airway health and sleep wellness.

Company

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on addressing dentofacial abnormalities, obstructive sleep apnea, and snoring through non-invasive treatment solutions. The company develops and commercializes the Vivos Method, an oral appliance-based approach used by trained dental and medical professionals to support airway health and sleep wellness. Its current offerings also include the VivoScore Program, which provides screening and home sleep testing for adults and children, along with related appliances, treatment protocols, and support services. Vivos Therapeutics works primarily with licensed professionals, especially general dentists, in the United States and Canada, positioning its products within the broader sleep-disordered breathing and oral appliance therapy markets. Based in Littleton, Colorado, the company serves as a specialized provider in the healthcare technology sector.

CEO Mr. R. Kirk Huntsman · 268 employees · United States · https://www.vivos.com